Trials / Completed
CompletedNCT00299806
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
A Multi-center, Open-label Study Assessing the Safety and Efficacy of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-03-07
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00299806. Inclusion in this directory is not an endorsement.